MedTrace Logo

Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3

NCT04268173 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 343

Last updated 2024-08-01

Study results available
· View outcomes & findings →

Summary

The goal of this study was to effectively use a client-centered community-based intervention to engage people who inject drugs (PWIDs) in healthcare that helps reduce risky behaviors and lower infectious disease risks. Participants in the intervention group of this study received a 12-week intensive multilevel harm reduction case-management intervention at three rural Vivent Health offices. Service coordination aimed to reduce human immunodeficiency virus (HIV), hepatitis C virus (HCV), and overdose risks in PWIDs. Prevention Navigators (PNs) at each office helped to coordinate referrals to reduce substance use disorder and increase engagement in the substance use disorder care cascades.

Conditions

  • Drug Use Disorders
  • Hepatitis C
  • Harm Reduction
  • Opioid-use Disorder

Interventions

OTHER

Community-Based, Client-Centered Prevention Home

Prevention Navigators at Vivent Helath offices will engage participants in risk assessments, goal planning, and treatment referrals based on their needs and desires.

Sponsors & Collaborators

  • Tulane University

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Ryan Westergaard, MD, PhD, MPH · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268173 on ClinicalTrials.gov